<?xml version="1.0" encoding="UTF-8"?>
<p>Randomized controlled trials (RCTs) remain the scientific ideal for evaluation of novel treatments. However, in studies on malignancies, RCTs are sometimes not sufficient to address the evidentiary requirements of regulating authorities
 <sup>
  <xref rid="b30-1040797" ref-type="bibr">30</xref>
 </sup> and payers as patients are selected on strict inclusion/exclusion criteria and sufficient data on overall survival and long-term follow up is often not provided.
 <sup>
  <xref rid="b31-1040797" ref-type="bibr">31</xref>
 </sup> In addition, the comparative arm in clinical trials may be chosen to favor the treatment of investigation. Therefore, regulating authorities increasingly look for real-world data for additional comparison when evaluating new cost-intensive drug regimens. However, reliable data on consecutive patients in routine health-care may be difficult to obtain.
</p>
